48 Participants Needed

Moxonidine for Postural Orthostatic Tachycardia Syndrome (POTS)

EC
VU
AD
Overseen ByAndre Diedrich, MD, PhD
Age: 18 - 65
Sex: Female
Trial Phase: Phase < 1
Sponsor: Vanderbilt University Medical Center
Approved in 6 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial requires participants to stop taking medications that affect autonomic function, blood pressure, or blood volume. If you are on such medications, you will need to withdraw from them to participate.

Is moxonidine safe for human use?

Moxonidine has been studied for its safety in treating high blood pressure, with common side effects including dry mouth, sleepiness, headache, and dizziness. Serious side effects are rare, and it does not worsen conditions like diabetes or interact negatively with certain medications. Overall, it has a good safety profile for managing mild-to-moderate hypertension.12345

How is the drug Moxonidine unique in treating POTS?

Moxonidine is unique for POTS as it primarily targets the sympathetic nervous system, potentially reducing the excessive heart rate increase seen in POTS by acting on specific receptors in the brain, which is different from other treatments that focus on blood pressure or volume expansion.678910

What is the purpose of this trial?

This trial tests Moxonidine, a medication that calms overactive nerves controlling blood pressure and heart rate, on patients with POTS who have high nerve activity. The goal is to see if it can lower heart rate and improve symptoms when standing. Moxonidine is designed to reduce blood pressure with fewer side effects compared to older medications.

Research Team

AD

André Diedrich, MD

Principal Investigator

Vanderbilt University Medical Center

Eligibility Criteria

This trial is for men and women aged 18-55 with Postural Orthostatic Tachycardia Syndrome (POTS) characterized by a rapid heartbeat upon standing. Participants must have high resting sympathetic nerve activity, not be pregnant or severely overweight, and cannot be taking certain medications that affect autonomic function.

Inclusion Criteria

I have had symptoms when standing for 6 months without any other sudden illness causing it.
You are in the first half of your menstrual cycle, between days 5 and 13 of a 28-day cycle.
I have been diagnosed with a specific type of POTS based on nerve activity tests.
See 3 more

Exclusion Criteria

I am not currently taking oral corticosteroids, have no infections, and am not using NSAIDs.
I have a condition like heart disease, high blood pressure, I smoke, have high cholesterol, arthritis, or diabetes.
You have a body mass index (BMI) over 30.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single oral dose of moxonidine or placebo to assess the effects on orthostatic symptoms and hemodynamics

Single dose administration
1 visit (in-person)

Observation

Participants are monitored for changes in heart rate and orthostatic symptom burden after administration

2-3 hours
Continuous monitoring during visit

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Moxonidine
  • Placebo
Trial Overview The study tests the effect of Moxonidine, a blood pressure medication that reduces sympathetic nerve activity, on POTS symptoms compared to a placebo. The goal is to see if it can lower heart rate and improve symptoms when standing in patients with high sympathetic activity.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MoxonidineExperimental Treatment1 Intervention
Patients will receive a single oral dose of moxonidine 0.4 mg.
Group II: PlaceboPlacebo Group1 Intervention
Patients will receive a single oral dose of placebo.

Moxonidine is already approved in European Union, Canada, China, Switzerland, United Kingdom for the following indications:

🇪🇺
Approved in European Union as Physiotens for:
  • Hypertension
🇨🇦
Approved in Canada as Physiotens for:
  • Hypertension
🇨🇳
Approved in China as Moxonidine for:
  • Hypertension
🇨🇭
Approved in Switzerland as Physiotens for:
  • Hypertension
🇬🇧
Approved in United Kingdom as Physiotens for:
  • Hypertension

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

In a study of 32 patients with congestive heart failure, a single dose of moxonidine significantly reduced elevated plasma norepinephrine levels and produced a dose-dependent vasodilator response, leading to lower systemic and pulmonary arterial pressures.
Moxonidine was well tolerated and demonstrated substantial hemodynamic improvements, suggesting that further trials are warranted to assess its long-term efficacy in combination with standard CHF treatments.
Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Dickstein, K., Manhenke, C., Aarsland, T., et al.[2019]
Moxonidine, administered for two weeks at doses of 2 or 10 mg/kg, significantly reduced cardiac sympathetic tone in stroke-prone spontaneously hypertensive rats by 24.3% and 32.2%, respectively.
The treatment also improved cardiac baroreflex function, increasing the baroreflex gain in a dose-dependent manner, which suggests that moxonidine effectively modulates heart rate control mechanisms.
[Effect of moxonidine on the cardiac chronotropic regulation in hypertensive rats SHR-SP].Khokhlova, ON., Murashov, AN., Lavrova, LN., et al.[2014]
In a study involving 4005 patients with hypertension, moxonidine significantly lowered blood pressure from an average of 168/97 mmHg to 141/83 mmHg over 8 weeks, with a response rate of 94% for all patients.
Moxonidine also contributed to a mean weight loss of 1.4 kg, particularly benefiting obese patients, while effectively managing blood pressure in those with metabolic syndrome.
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.Sharma, AM., Wagner, T., Marsalek, P.[2017]

References

Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. [2019]
2.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Effect of moxonidine on the cardiac chronotropic regulation in hypertensive rats SHR-SP]. [2014]
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. [2017]
Safety and tolerability of moxonidine in the treatment of hypertension. [2018]
I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. [2019]
Orthostatic and non-orthostatic headache in postural tachycardia syndrome. [2011]
[Postural orthostatic tachycardia syndrome]. [2017]
[Postural orthostatic tachycardia syndrome]. [2017]
Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome. [2017]
The incidence of postural orthostatic tachycardia syndrome in the population of Zagreb, Croatia. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security